News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
This rating reflects Lupin's leadership in environmental transparency and performance
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
